GlassScriptPhysician profile
Linda L Wang
NPI 1649563180
$6,589.08
in general payments reported to CMS, 2019-2025
20 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $676 · 2021: $930 · 2022: $594 · 2023: $1,018 · 2024: $1,430 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,604.59 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,342.98 | 2020-2025 | Krystexxa |
| Viiv Healthcare Company | $869.35 | 2022-2025 | Apretude |
| Lilly USA, LLC | $612.21 | 2022-2025 | Mounjaro |
| Allergan, INC. | $249.97 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $240.16 | 2019-2021 | |
| Boston Scientific Corporation | $200.79 | 2023-2025 | General - Pain Management |
| Abbvie INC. | $138.88 | 2021 | |
| Horizon Therapeutics Plc | $133.41 | 2019 | |
| Glaxosmithkline, LLC. | $125.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2020 | |
| Akebia Therapeutics INC | $124.47 | 2019 | |
| Vifor Pharma, INC. | $122.81 | 2021 | |
| Travere Therapeutics, INC. | $122.43 | 2024 | |
| Novo Nordisk INC | $119.85 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $117.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.06 | 2024 | Jardiance |
| Gilead Sciences, INC. | $107.07 | 2024 | Descovy |
| Merck Sharp & Dohme LLC | $100.00 | 2022 | |
| Covidien LP | $18.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.